US Patent

US12097187 — Opioid receptor modulator dosage formulations

Method of Use · Assigned to Allergan Holdings ULC · Expires 2033-03-14 · 7y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects abuse deterrent solid dosage formulations of a specific opioid receptor modulator and processes for preparing and administering these formulations.

USPTO Abstract

Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6 -dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy -benzoic acid, and processes for the preparation and administration of these formulations.

Drugs covered by this patent

Viberzi (ELUXADOLINE) · AbbVie

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3475`	—	Viberzi

Patent Metadata

Patent number: US12097187
Jurisdiction: US
Classification: Method of Use
Expires: 2033-03-14
Drug substance claim: No
Drug product claim: No
Assignee: Allergan Holdings ULC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.